Title : Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.

Pub. Date : 2013 Jan

PMID : 23200175






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Selumetinib is an inhibitor of MEK1/MEK2, downstream of KRAS, with preclinical evidence of synergistic activity with docetaxel in KRAS-mutant cancers. AZD 6244 mitogen-activated protein kinase kinase 2 Homo sapiens